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Abstract
Selective immunoglobulin A deficiency (SIgAD) is the most 
prevalent type of primary immunodeficiency disorder. The 
phenotypic feature of SIgAD is related to a defect in B lym-
phocyte differentiation into plasma cell-producing immu-
noglobulin A (IgA). In this review, we summarize the recent 
advances in this regard. Genetic (including major histocom-
patibility complex [MHC] and non-MHC genes), immunolog-
ic (including B and T lymphocyte subsets abnormality), cyto-
kines/chemokines and their related receptors, apoptosis and 
microbiota defects are reviewed. The mechanisms leading 
to SIgAD are most likely multifactorial and it can be specu-
lated that several pathways controlling B cells functions or 
regulating epigenetic of the IGHA gene encoding constant 
region of IgA heavy chain and long-term survival of IgA 
switched memory B cells and plasma cells may be defective 
in different SIgAD patients. © 2019 S. Karger AG, Basel
Introduction
Immunoglobulin A (IgA) is the second dominant iso-
type in the blood circulation following IgG. In humans, 
there are 2 subclasses of IgA: IgA1 (main IgA subclass) 
and IgA2 (secreting in large bowel and least in the jeju-
num). IgA can be found in both monomeric and dimeric 
forms; circulating IgA is in monomeric form, whereas se-
cretory IgA, in the mucosal secretions of respiratory, in-
testinal, and genitourinary systems, is dimeric. The mo-
nomeric structure of serum IgA has 2 heavy chains, each 
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consisting of one variable and 3 constant regions, and 2 
light chains, each of which is made up of one variable and 
one constant region [1].
Predominantly antibody deficiencies are the most fre-
quent type of primary immunodeficiency disorders 
(PIDs), with more than 13,000 symptomatic patients reg-
istered globally (~20% of all reported PID patients to 
date) [2]. Selective immunoglobulin A deficiency 
(SIgAD), the most prevalent of PID, is characterized by 
decreased serum IgA level lower than 7 mg/dL in indi-
viduals older than 4 years with normal levels of IgM and 
IgG in serum and exclusion of other causes of hypogam-
maglobulinemia. These patients have normal IgG anti-
body response to all vaccinations but might be associated 
with a non-prominent T cell defect [3]. The prevalence 
varies due to the different ethnics, such as 1: 142 in the 
Arabian Peninsula [4], 1: 300–1: 700 in Iran [5], 1: 600 in 
the Caucasian population [6], and 1: 18,500 in Japan [7]. 
The prevalence of SIgAD in Chinese population is higher 
compared to Japanese populations, 1: 4,100 among 6 na-
tionalities in China [8] and 1: 1,615 in Chinese blood do-
nors [9].
IgA deficiency demonstrates heterogeneous pheno-
types – ranging from being benign, with asymptomatic 
individuals and diagnosed coincidentally through blood 
donor screening, to being problematic and symptomatic 
with different clinical manifestations including mild re-
current sinopulmonary infection, autoimmunity, allergy 
and occasionally with severe immunologic complications 
[10]. Based on the several efforts to clarify the etiology 
and pathogenesis of SIgAD, the major problem is the fail-
ure of B lymphocyte to produce IgA [11, 12]. However, 
other abnormalities such as increased lymphocytic apop-
tosis, cytokine network, signaling pathway by costimula-
tory molecules and also the presence of predisposing ma-
jor histocompatibility complex (MHC) alleles might be 
involved in the pathogenesis of SIgAD [13–15]. 
Bringing this condition to a broader audience can help 
enlighten the enigmatic etiology and pathogenesis of 
SIgAD as a vital step for better understanding of the dis-
ease mechanism and better management of affected indi-
viduals. In this review, we summarize the recent advanc-
es in the field of SIgAD.
Pathogenesis of SIgAD
Recent findings have proposed that patients with 
SIgAD have defects in the process of IgA class switch re-
combination (CSR), production, and secretion of IgA as 
well as long-term survival of IgA switched memory B cells 
and plasma cells. These 4 main steps in the generation and 
maintenance of serum IgA level may be affected by ge-
netic susceptibility elements, cytokines and their recep-
tors milieu and gut microbiota, that are explained in next 
sections (Fig. 1). 
Genetic Susceptibility
From a genetic point of view, 3 chromosomes includ-
ing 18, 14, and 6 have been significantly associated with 
IgA deficiency according to the genome-wide association 
studies [16]. In this sense, the mode of inheritance is not 
fully understood; certain human leukocyte antigens 
(HLA) haplotypes and non-HLA genes have been associ-
ated with IgA deficiency. Modifying genetic factors and 
genetic associations, which may contribute either to the 
pathogenesis of the IgAD or other visible complications 
among patients, were suggested by studies that evaluated 
the underlying genetic defects of patients. In reported fa-
milial cases, inheritance of IgA deficiency is either auto-
somal dominant or autosomal recessive based on the ped-
igree analysis, but sporadic cases show no genetic asso-
ciations [16, 17]. To date, identified defects of both MHC 
and non-MHC genes are summarized in the following 
sections.
MHC Genes 
Since 1970, there are ongoing researches towards find-
ing associations of HLA and IgAD predisposition which 
identified different loci of MHC regions [18–22]. Common 
genetic associations of the happenstance manifestations 
like autoimmunity, inflammatory complications, and ma-
lignancies in IgA-deficient individuals has helped to ex-
plore predisposing alleles of SIgAD [3, 23–25] (Table 1).
Except the geographical clustering of the association 
between HLA haplotypes and SIgAD occurrence, collec-
tively, HLA A1, B8, B12, B13, B14, B40, DR1, DR2, DR3, 
DR7, DR11, DQ2, DQ3, and DQ5 alleles have been asso-
ciated with SIgAD, either in a protective or predisposing 
pattern [22, 26–30]. Up to now, homozygosity and het-
erozygosity for the HLA-B8-DR3-DQ2, HLA-DR7-DQ2, 
and HLA-B14-DR1-DQ5 haplotypes have constituted 
strong risk factors for the development of SIgAD, while 
HLA-DR15-DQ6 has protected against SIgAD [21, 29, 
31, 32]. Due to the linkage disequilibrium across MHC 
alleles, haplotypes containing aforementioned alleles can 
be related to other genes; thus, it is highly recommended 
to study single HLA genes, specific heterodimers, and 
complex interactions between alleles at multiple genes in 
MHC region.
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The contribution of the HLA class II genes in suscep-
tibility to SIgAD is determined in the context of HLA-
DQB1*02: 01, HLA-DQB1*0202, HLA-DRB1*01: 02, 
HLA-DRB1*0301, and HLA-DRB1*0701 [33], while the 
highly protective association is reported for HLA-
DRB1*15: 01 allele. Moreover, a negative association be-
tween HLA-DR2-DQB1*0602 alleles were indicated. Risk 
alleles located between BTNL2 and HLA-DRA regions 
are in linkage disequilibrium with HLA-DRB1*15: 01 and 
suggested to play a protective role in SIgAD too [30, 33]. 
Other allelic mutations among included genes in MHC 
region are also reported in patients with SIgAD such as 
MSH5, which itself showed contrast association with 
HLA-B14-DR1 and HLA-B8-DR3 haplotypes, and IGAD1 
which has a locus within HLA-DQ/DR located at the telo-
meric part of the class II region or the centromeric part of 
the class III region of the MHC [27, 34, 35]. There are also 
some complement encoding genes that have been suggest-
ed to be connected with the pathogenesis of IgAD, most 
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Fig. 1. IgA class switching in the gut. There are two pathways of 
IgA CSR to the dependency on T cells. TD pathway happens in 
germinal center and needs B and CD4+ T cell interaction through 
CD40-CD40L and TGF-β1 production (Orange circle). TID IgA 
CSR occurs by engagement of different receptors, transcription 
factors, and cytokines such as nitric oxide, retinoic acid, IL-6, 
TACI, BAFF, APRIL, and TSLP in lamina propria (Green circle). 
TGF-β1 plays its role via SMADs, RUNX3 to induce IgA CSR. DCs 
by antigen capturing and presenting or secretion of cytokines are 
important in both 2 pathways. After class switching, DCs and epi-
thelial cells via APRIL, BAFF and IL-10 induce plasma-cell differ-
entiation. MHC, major histocompatibility complex; IgA, immu-
noglobulin A; TACI, transmembrane activator and CAML inter-
actor; TGF-β, transforming growth factor beta; CSR, class switch 
recombination; NO, nitric oxide; RA, retinoic acid; TID, T-cell-
independent.
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Table 1. Proposed genetic etiologies underlying IgA deficiency
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Motility and respiratory burst of
phagocytes
Phagocyte defectiveness [137–142]






IFIH1 Encodes MDA5 (a cytosolic receptor
that recognizes
dsRNA and initiates interferon
pathway activation)
[144, 145]
CXCR4 A CXC chemokine receptor gene [146, 147]
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HLA III region. The presence of proper MHC molecules 
play an important role in presenting antigen from B cell 
to T follicular helper (TFH) cell and the consequent cyto-
kine production. This helps in ensuring optimum estab-
lishment of long lasting IgA switched memory B cell and 
plasma cell. Altogether, the complex and multi-locus 
MHC associations leading to predisposition/protection of 
IgAD needs to be clarified to shed light on the exact un-
derlying pathogenesis of SIgAD. Interestingly, consistent 
with previous analytical studies of HLA, it has been man-
ifested that unusual HLA markers in SIgAD patients pre-
dict the possibility of progression to common variable im-
munodeficiency disease (CVID) [28, 29, 36].
Non-MHC Genes 
It has been manifested that MHC locus performs the 
most important role in both immunologic response and 
tolerance; however, non-MHC genes are also considered 
as a cause of many immunological deficiencies. To ad-
dress the potential genes arising from selective IgA defi-
ciency, we summarized the non-MHC genetic defects of 
individuals who had reduced IgA levels as a common clin-
ical manifestation. Among the involved molecules in the 
T cell receptor signaling, costimulatory mechanisms, and 
DNA repair systems, gene defects have been reported. In 
this category, JAK3 and RAG1 genes and some of the oth-
er mutated genes are illustrated in Table 1. Thymic func-
tions and epigenetic markers are also reported to be defec-
tive through mutated genes; like ATM gene, a coding ele-
ment of an involved protein in the nervous and immune 
system. It has also been demonstrated that some respon-
sible genes in the B cell receptor (BCR) signaling, like BTK 
and transmembrane activator and CAML interactor, are 
modifying factors in a number of IgAD individuals. There 
are some other reported non-MHC gene mutations in im-
mune disorders who had IgAD (Table 1) [15, 37]. Non-
MHC loci polymorphism of some genes listed in Table 1 
have been reported to be associated with SIgAD [38].
Name Function Immune disorders with
common predisposing locus
Reference
STAT1, STAT2, STAT3, 
IL12RB1, and C3
Inducer of involved factors of cell viability




NLRP12, and MVK Auto inflammatory disorders
genes affecting the inflammasome
Polymorphism
CLEC16A Negatively regulates autophagy via
modulation of mTOR activity
Autoimmune diseases including 
MS, T1D, SLE, and Celiac disease
[38, 145, 151, 152]










upregulated in breast cancer
TM7SF3 Maintenance of protein homeostasis
and promoting cell survival through
attenuation of ER stress
CTLA4, ICOS, FAS Immune checkpoint protein Graves’ disease
TNFAIP3 Inhibition of NF-kB activation Autoimmune diseases
including SLE
IL-10 Anti-inflammatory cytokine
IL6 Stimulation of acute phase responses,
hematopoiesis, and immune reactions
PVT1 Oncogenic long noncoding RNAs RA
Table 1. (continued)
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From the discovery time of IgAD, Ig heavy-chain con-
stant region (C) gene alpha (IGHA) and Iα germline tran-
script (α-GLT) were the most suspected responsible ele-
ments for SIgAD. In 1984, Migone et al. [39] showed large 
DNA deletion in the constant region of Ig heavy chain in 
2 patients with reduced serum Igs. In 1991, more single 
and multigene deletions were found in the Ig CH locus of 
15 Tunisian individuals who lacked several immunoglob-
ulins [39, 40]. 
During an investigation about the molecular events 
leading to IgA production in IgAD patients, in 1994, Is-
lam et al. [41] indicated a significant decrease in the num-
ber of switch (S) mu/S alpha fragments in unstimulated 
peripheral blood mononuclear cell (PBMC) of IgAD pa-
tients. The membrane mRNA expression of C alpha in 
unstimulated PBMC decreased along with C alpha mRNA 
levels and IgA production in PWM-stimulated PBMC. 
Therefore, a failure to switch to IgA-producing B lym-
phocytes or a compromised survival of such cells were 
suggested to be causal in IgA deficiency [41]. Moreover, 
in 1999, Wang et al. [42] found a low expression of both 
secreted and membrane forms of productive C alpha 
mRNA in IgA-switched B cells and impaired IgA switch-
ing. Therefore, a direct link to low IgA secretion and a 
blockade in post-IgA switch differentiation of B cells was 
suggested in IgA-deficient subjects who were homozy-
gous for HLA-B8, SC01, DR3 haplotype [42]. However, 
Asano et al. [43] found reduced α-GLT expression and 
absence of α circle transcripts in SIgAD in contrast to par-
tial IgAD patients; they studied a group consisting of 3 
SIgAD and 3 partial IgAD patients to clarify the probable 
stage in which B cell differentiation may be blocked. 
Among SIgAD patients, they observed normal induction 
of α-GLT and α circle transcript after stimulations with 
phorbol myristate acetate and transforming growth fac-
tor beta (TGF-β) as well as IgA secretion via stimulation 
with anti-CD40, IL-4, and IL-10. These observations were 
different in partial IgAD patients. Consequently, they es-
tablished the importance of decreased expression level of 
α-GLT in the pathogenesis of SIgAD [43]. In 2006, how-
ever, Hummelshoj et al. [44] showed a reduced GLT-α 
and activation-induced cytidine deaminase (AID) ex-
pression upon stimulation of naïve IgD+ B cells with 
TGF-β, IFN-γ, and IL-10 in IgAD individuals and pro-
posed that a low α-GLT underlies low level of productive 
IgA and further differentiation into plasma cells. In 2009, 
a combination of IL-21, IL-4, and anti-CD40 stimulation 
induced CSR (α- and γ-GLT) to IgG and IgA and differ-
entiation of Ig-secreting cells in CVID or IgAD patients 
[45]. 
Taken together, a much debated question exists wheth-
er a defect in the IGHA gene and associated genetic dis-
order causes IgA deficiency or epigenetic modifications 
and non-genetic events. Recent investigations have sug-
gested post-switch defects hypothesis, including intrinsic 
transcriptional defects in B cells or a lack of proper acti-
vating signals for the IGHA gene that we have discussed 
in next sections. Furthermore, according to a recent in-
teresting study, an intron-encoded microRNA (called 
miR-6891-5p) by HLA-B locus has been described for its 
functional role in modulating the expression of IGHA1 
and IGHA2 [46], which presents a post-transcriptional 
hurdle in the IgA production process.
Except for the predefined paradigm of cytogenetic ab-
normalities (e.g., 4p monosomy, trisomy 8, trisomy 10p, 
translocation of 10q to 4p, 17p11.2 deletions, 18q-syn-
drome, trisomy 21, monosomy 22, and 22q11.2 deletion 
syndrome) [15] and HLA haplotypes association for 
SIgAD pathogenesis, monogenic mutations should be 
considered as a separate etiology [13]. The strategy to 
classify IgA-deficient patients in homogenized groups 
will be helpful in SIgAD pathogenesis, besides taking an 
imbalanced genetic approach using high-throughput se-
quencing.
Immunologic Defects
Correct immunological interactions originate from an 
intact genetic content. A phenotypic immunological fea-
ture might reflect the underlying genetic background de-
fects in SIgAD patients. In this line, several immunologic 
perturbations can account for an impaired B-cell matura-
tion, plasma cell differentiation, and long-term IgA pro-
duction in SIgAD patients. These immunologic dysregu-
lations have been observed from abnormal bone marrow 
progenitors and mature B cells profile to inadequate ex-
pression of costimulatory molecules or production of cy-
tokines at local sites of B-cell proliferation, including pri-
mary and secondary lymphoid tissues. Therefore, one of 
the most important causes of SIgAD is related to numer-
ical and functional defect in B lymphocytes and other im-
mune system components [13].
Hematopoietic Stem Cells
Stem cells are the undifferentiated class of cells that 
have a potential to differentiate into different cell types 
such as immune precursors. In 1985, Hammarström et al. 
[47] showed that IgA deficiency can be transferred to re-
cipients by bone marrow transplantation from an IgA-
deficient donor. On the contrary, in 1991, Kurobane et al. 
[48] showed that bone marrow transplantation from a 
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normal individual could correct the impairment of IgA 
production. These 2 studies suggest the possibility of de-
fects in stem cells of IgA-deficient patients. However, to 
develop a full picture of bone marrow transplantations’ 
efficacy in IgA-deficient patients, additional studies will 
be needed as side effects may arise, as experienced in pa-
tients with CVID [49].
B Cell Subsets
Few studies have evaluated the measurement of B-
lymphocyte subsets in SIgAD patients [11, 12, 50–52]. 
Litzman et al. [52] reported that there was no significant 
abnormality in the B-cell subsets of IgAD patients. How-
ever, further studies indicated decreased class-switched 
memory B cells in SIgAD patients [11, 12]. In this line, we 
indicated in one study that there are 2 subgroups of pa-
tients with IgAD (group I and II) based on switched 
memory B cells percentage [50]. In patients with group I, 
the percentage of switched memory B cells are less than 
0.4%, while in patients with group II the percentage of 
switched memory B cells are more than 0.4%. Based on 
this categorization, we found that patients with low-
switched memory B cells exhibited more severe clinical 
features, including pneumonia, bronchiectasis, and auto-
immune diseases than group II [50]. The classification of 
SIgAD patients by assessment of switched memory B cells 
could help physicians with the clinical prognosis for these 
patients.
Nechvatalova et al. [11] evaluated similarities between 
CVID and IgAD based on the determination of B-lym-
phocyte subsets. They indicated a decrease in the fre-
quency of switched memory cells, transitional cells as well 
as plasmablasts, and an increase in the CD21low B cell sub-
set compared to healthy individuals [53, 11]. In this sense, 
Celiksoy et al. [51] demonstrated high counts of naive B 
cells in patients with SIgAD similar to CVID patients. On 
the contrary, it has been evident that increase of naïve B 
cells have an association with autoimmunity occurrence 
and it can similarly be observed in the autoimmune pa-
tients with IgA deficiency and other forms of antibody 
deficiency (e.g., selective IgM deficiency, and CVID) [51, 
54]. Since there is evidence about the progression of 
SIgAD towards CVID, the immunologic profile associa-
tion of these 2 antibody deficiency is logical [55].
T Cell Subsets
Antibody isotype switching and production can be in-
fluenced by different subpopulations of T cells and are 
also important in the B cell maturation in the germinal 
center. However, in some studies, investigators have 
demonstrated no significant difference between SIgAD 
patients and healthy controls for any of the measured T-
cell subpopulations (CD3+, CD4+, CD8+, naïve, memory, 
and differentiated T cells) and the proliferation index and 
the percentage of divided cells [11, 12]. Moreover, Lemar-
quis et al. [12] assessed effector T cell subpopulation func-
tions and have shown that the activity of TH1, TH2, 
TH17, TH22, and T TFH cell are comparable in SIgAD 
patients compared to healthy controls. Only one study by 
our group has reflected a defect in regulatory T cells 
(Tregs) in SIgAD patients with autoimmunity [56]. The 
recent group also reported comparable function for natu-
ral Tregs (nTregs) and induced Tregs (iTregs) between 
SIgAD patients and healthy controls. Similarly, the diag-
nostic criteria suggested by the European society for im-
munodeficiency include the exclusion of T cell defects in 
the SIgAD patients (https://esid.org/Working-Parties/
Registry-Working-Party/Diagnosis-criteria).
Receptor Defects
It has been recently demonstrated that a defect in dif-
ferent immune receptors could be involved in the patho-
genesis of SIgAD. T-cell-dependent (TD) pathway drive 
B cells in germinal center after interaction with TFH 
through CD40 ligand (CD40L)-CD40 and TGF-β1 pro-
duction (Fig. 1). TGF-β1 has an important role in the 
induction of IgA CSR via different transcription factors 
such as SMAD, Runt-related transcription factor 3 
(Runx3), and PU1. This happens through the involve-
ment of CD40L on the CD4+ T cells to induce nuclear 
factor kappa light chain enhancer of activated B cells 
(NF-κB) activation, which activates activation-induced 
cytidine deaminase expression as a crucial requirement 
of CSR. T-cell-independent (TID) IgA CSR occurs by 
engagement of different receptors, transcription factors, 
and cytokines such as toll-like receptor, B BCR, nitric 
oxide (NO), retinoic acid (RA), IL-6, TACI, BAFF, A 
proliferation-inducing ligand (APRIL), and thymic 
stromal lymphopoietin. There are, however, other pos-
sible theories such as the theory of antibody against cy-
tokine and cytokine receptors. Therefore, defective re-
ceptors or disturbed signaling pathways of each of these 
factors might be involved in IgA-deficient patients [57–
59]. 
IgA Expression as a BCR
B cells use their antigen receptor to capture small 
amounts of their specific target and to present peptide 
antigens to T cells; so, low levels of surface IgA expression 
may lead to low capacity of those B cells to present anti-
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gens, and therefore they do not receive adequate co-stim-
ulation for their terminal differentiation. The surface ex-
pression of IgA is necessary for IgA secretion process. It 
has been indicated that the expression of the membrane 
and secreted IGHA gene decreased, and it may be one of 
the post class switch defects causing IgA deficiency [42]. 
Nevertheless, Schaffer et al. [60] reported normal per-
centages of IgA B cells and normal levels of surface IgA 
expression in some IgA-deficient patients, suggesting a 
defect in secretion of IgA but not IgA expression. These 
results cannot exactly explain the IgA expression’s defect 
in SIgAD patients and further studies with more focus on 
the surface expression of IgA on B lymphocyte are there-
fore suggested. 
TGF-β Receptor
The IgA CSR and secretion can be induced via TGF-β 
dependent and independent mechanisms. Using mouse 
model that selectively lack TGF β receptor on B cells, 
some studies have reported a defect in IgA production, 
especially in mice with defect in TGF-β receptor II than 
in those with deficient TGF-β receptor I [61, 62]. Al-
though decreased IgA secretion in TGF-β receptor defi-
cient mouse model demonstrated the possible role of this 
pathway in human SIgAD, to clarify a full picture of the 
role of TGF-β receptor in the pathogenesis of SIgAD, ad-
ditional studies are required. SMAD proteins act as tran-
scriptional factors and transducers in the TGF-β1 signal-
ing pathway. A strong relationship has been reported be-
tween SMAD3, SMAD4, and SMAD7, and regulation of 
IgA-CSR [59]. In this line, overexpression of SMAD3 and 
SMAD4 selectively increase IgA production and surface 
expression, besides, SMAD3 deficient mice model found 
with no IgA. On the contrary, SMAD7 (as an inhibitor of 
TGF-β receptor signaling) deficient mice model have in-
creased CSR towards IgA, so over activity of this check-
point inhibitors can also decrease the IgA production. It 
has also been shown that SMAD7 abolishes the synergis-
tic effect of SMAD3 and SMAD4 on IGHA promoter ac-
tivity [63–65]. Moreover, acute myeloid leukemia and 
CAMP-response element-binding protein transcription 
factors have been shown to collaborate with SMADs to 
activate the transcription of α-GLT in response to TGF-β 
[66]. In addition to these factors, lymphocytes of mice 
with Rel-A (NF-kB subunit also known as p65) deficiency 
present a selective defect in the secretion of IgG1 and IgA, 
which suggests a candidate for future studies [67]. There-
fore, defect in TGF-β receptors and down stream’s tran-
scription factors can have an important role in SIgAD. 
Despite these promising findings, the role of defects in 
these transcription factors in human SIgAD remains un-
clear and further studies, which take these variables into 
account in a human study, will need to be undertaken. 
IL-10 Receptor
Differences in cytokines and their receptors exist 
within IgA-deficient patients. Several researches have 
focused on the phenotypic heterogeneity in IgA-defi-
cient patients. They have found that under suitable 
stimulations, B cells of healthy IgA-deficient individu-
als synthesize considerable amounts of IgA [68]. But B 
cells from infection-prone IgA-deficient patients pro-
duce only minute levels of IgA. So these data suggest 
that the abnormalities of B cell differentiation in IgA 
deficiency can be compensated by cytokine stimulation 
but they react heterogeneously [69, 44]. Another im-
portant finding by further investigations were that 
stimulation of IL-10/IL-10 receptor is not sufficient to 
induce IgA production and interestingly with addition-
al IL-4 in the culture media a higher amount of IgA can 
be produced [44, 70]. Similar to these observations, in 
1998, it has been shown that IL-10 stimulation leads to 
increased IgA in IgA-deficient subjects, but not in IgA 
level production of healthy controls. The synergizing 
effect of IL-4 and IL-10 on IgA production in IgA-de-
ficient group, specifically to IgA isotype, has also been 
asserted [70]. Borte et al. [45], however, reported a 
higher efficiency of stimulation with IL-21 compared to 
stimulation with IL-10 or IL-4, because IL-21 is one of 
the important promoters of human B cells differentia-
tion into plasma cells. Nevertheless, IL21 gene sequenc-
ing did not reveal any mutations and there were no de-
fects in the analysis of IL-21 receptor and IL-21 mRNA 
expression in SIgAD patients, so IL21 can be a potential 
therapeutic agent to reconstitute antibody production 
in SIgAD patients [45]. This result has raised a question 
whether a probable defect in IL-10/IL-10 receptor re-
sponse exists in these patients. Interestingly it was 
shown that in contrast to IL-10 other members of the 
interleukin-10 subfamily (IL-19, IL-20, IL-22, IL-24, IL-
26, IL-28, and IL-29) failed to induce the production of 
any immunoglobulin by stimulation of purified naive B 
cells [71]. It should be noted that no defects were ob-
served in IL-10 production in SIgAD patients [72]. 
 Despite many unanswered questions about molecular 
mechanisms of an IL-10 signaling pathway, it can be 
hypothesized that lack of TGF-β receptors up-regula-
tion cause IgA deficiency and IL-10 may be a prerequi-
site for TGF-β II receptor expression and subse-
quent deliverance of the class switch signal. These rela-
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tionships may be partly explained by the finding that 
IL-10/IL-10 receptor interaction has the capability to 
enhance TGF-β receptor II expression on activated T 
cells [73].
BAFF and APRIL Receptors 
Another possible reason for the production of defec-
tive IgA can be a defect in related co-stimulatory BCRs 
and their signaling pathways. As noted, BAFF (B-cell ac-
tivating factor) and APRIL are 2 important cytokines in 
TID IgA CSR. B cells express 3 receptors for these cyto-
kines, including TACI, BAFF receptor (BAFF-R), and B-
cell maturation antigen. APRIL interacts with TACI and 
B-cell maturation antigen but BAFF can bind to all 3 re-
ceptors [74]. BAFF is a positive regulator of B cells which 
enhances B-cell survival, and with low probability, its de-
fect cannot lead to just IgA deficiency, because BAFF-R 
and BAFF knockout (KO) mice are deficient in B cells and 
they cannot be used to investigate the requirements of 
IgA induction [75]. Although it reported two siblings 
with CVID that carry a homozygous deletion in the 
BAFF-R gene, have lower IgM and IgG serum levels but, 
unlike most CVID patients, they have normal IgA con-
centrations [76]. 
TACI or TNFRSF13B (tumor necrosis factor recep-
tor superfamily member 13B), encoded by the TNFRS-
F13B gene, is a transmembrane protein of the TNF re-
ceptor superfamily. TACI has an important role in anti-
body responses against different types of antigens. 
Several polymorphic mutations have been found in the 
TNFRSF13B gene in IgA-deficient individuals, which is 
discussed in the genetic defects section. It has been man-
ifested that TACI-KO mice have low immunoglobulin 
levels, particularly IgA and present weak immune re-
sponses to TID antigens [77, 78]. Findings from several 
animal studies have indicated inappropriate levels of 
TACI signaling in the disruption of the immune system 
and promotion of autoimmune disorders [79]. Further-
more, in 2005, Castigli et al. [80] showed that in vitro 
stimulation of murine B cells using APRIL via TACI ac-
tivation leads to IgA, IgG and IgE CSR, while TACI-
deficient B cells were not able to switch to IgA when 
stimulated by BAFF in spite of their capability to switch 
to IgG and IgE. Thus, it seems that interactions of 
APRIL-TACI is necessary for IgA production [59, 80]. 
This is in contrary to the findings by Bacchelli et al. [81] 
that suggested an insignificant role of TACI in IgA CSR 
in vivo despite the previously observed evidence in vitro. 
So, further progress in determining the correct role of 
these factors in SIgAD patients is required.
CD40L Receptor 
T lymphocyte cells are important in IgA CSR via 
CD40/CD40L interaction, which is expressed on activat-
ed TFH and provides the second signal for TD CSR. 
Therefore, defective immunoglobulin production has 
been speculated to be due to an impaired or decreased 
helper T-cell activity in some SIgAD patients [52]. Cas-
sidy et al. [82] compared the ability of SIgAD patients’ T 
cells to help antibody production via normal B cells, sur-
prisingly, no differences were found in the production of 
IgM, IgG, and IgA, either in the presence of normal or 
patients’ T cells. T cells of SIgAD patients did not sup-
press IgA production and surprisingly helped the pro-
duction of IgA [82, 83]. On the contrary, there are sev-
eral evidences that have shown the correct IgA produc-
tion when a deficiency exists in CD40 or CD40L in 
humans and mice, for instance, in experimental murine 
with rotavirus infection, virus clearance was achieved via 
induction of specific IgA, even in T-cell deficient animals 
[59, 84, 85]. Although some studies have proposed a pos-
sible CD40L deficiency in SIgAD patients, B cells of pa-
tients showed a reduced proliferative response to CD40L 
[86], and further support the idea that the probability of 
T-cell deficiency in SIgAD patients is low.
Chemokine Receptors
Aside from accuracy of stimulators in IgA production 
machinery, B cell homing to peripheral and mucosal tis-
sues have an important role for IgA production and secre-
tion for long-term memory B cell generation and hom-
ing/survival of plasma cells within the bone marrow. B 
cell homing is mediated by specific adhesion molecules 
and chemokine receptors such as CCR9, CXCR4, and 
CCR10 that are important for homing to the small intes-
tine and bone marrow by CCL25 ligand and CCL28 li-
gand, respectively [87]. A recent study showed that the 
proportion of the mucosal CXCR4, CCR10, and α4β7 
homing receptors expression are comparable in SIgAD 
individuals and healthy controls [12]. Although some 
studies have shown that expression of homing receptors 
are normal in SIgAD patients but more broadly, research 
is also needed to prove these results.
Cytokine Network Defects
A balanced and tuned cytokine profile are other im-
portant elements of signaling that are generally required 
for CSR. They activate transcription of promoters located 
in the upstream of CH exons and former switch region 
[59, 88]. This cytokine profile may be changed due to the 
abnormality of B-, T-, and dendritic cells (DC) interac-
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tions since the generation of signals for B cell differentia-
tion into IgA-producing cells requires this network. As 
mentioned earlier in cytokine receptors’ section, there are 
several cytokines that induce IgA CSR and terminal dif-
ferentiation of stimulated B lymphocyte. The major cyto-
kine for IgA CSR is TGF-β which works with the contri-
bution of other interleukins, such as IL-2, IL-4, IL-5, IL-6, 
and IL-10 [58, 59]. The ability of SIgAD patient’s PBMCs 
for producing several cytokines was analyzed; however 
only an increased production of TNF has been observed, 
suggesting that TNF may be involved in the regulation of 
IgA production [89]. In 1995, Müller et al. [90] have re-
ported reduced serum levels of TGF-β in SIgAD patients. 
However, some studies reported no difference in the plas-
ma level of TGF-β1 and TGF-β1 mRNA expression of B 
cells between SIgAD patients and controls [43, 45, 90]. 
Although TGF-β1 dysregulation might be a contributing 
factor in the pathogenesis of SIgAD, it should be noted 
that B cells generally undergo the CSR in the secondary 
lymphoid organs and it would be more valuable to ana-
lyze TGF-β1 expression in germinal centers. 
DCs of the Peyer’s patches and other mucosal associ-
ated lymphoid organs are involved in IgA CSR via sev-
eral cellular interactions. DCs activate latent form of 
TGF-β1 by induction of the processing of a latency asso-
ciated peptide, presenting bacterial products to B cells 
and secreting necessary cytokines for IgA CSR, such as 
TGF-β, IL-10, BAFF, and APRIL (Fig. 1) [91]. Among dif-
ferent types of DCs, intestinal DCs constitutively secrete 
RA in both humans and mice. RA has an important role 
in both TD and TID IgA CSR [87, 92]. In addition, RA is 
involved in plasma cell differentiation and CCR9 expres-
sion that are essential for homing of naive B cells to the 
small intestine [93, 94]. Runx3 plays a key role in IgA CSR 
as an acting molecule downstream of RA and TGF-β1 
signaling, and IgA production is blocked in Runx2-Runx3 
double-deficient mice [93]. However, Park et al. [95] 
found RA to act through RA receptor pathway, where 
neither Runx3 nor SMAD3/4 is involved, and SIgAD may 
be caused by a defect in RA receptor signaling pathway. 
In addition, DCs have an important enzyme entitled ni-
tric oxide synthase (NOS) that catalyze the production of 
NO from L-arginine. It has been reported that IgA CSR is 
impaired in inducible NOS KO deficient mice. Transfer-
ring wild-type DCs to inducible NOS KO mice rescued 
IgA production in these mice. On the contrary, it has been 
indicated that the Runx3 (as a RA downstream molecule) 
is significantly low in iNOS-deficient B cells [96]. Thus, 
due to the important role of DCs in CSR process, defects 
in RA and iNOS signaling may be involved in the patho-
genesis of SIgAD; however, further studies on above-
mentioned molecules and factors are needed in humans.
BAFF and APRIL are 2 important cytokines in TID 
IgA CSR. BAFF KO mice showed a slight decrease in mu-
cosal and serum IgA levels. However, APRIL KO mice 
had normal serum IgA levels and mucosal IgA levels 
comparable to wild-type mice; however, IgA producing 
plasma cells in the lamina propria were reduced in APRIL-
deficient mice [97, 98]. On the contrary, APRIL and BAFF 
plasma levels of SIgAD and CVID patients were signifi-
cantly higher than those of healthy children. These find-
ings indicate that APRIL and BAFF may be involved in 
the pathogenesis of SIgAD [99]. 
Peyer’s patch organogenesis requires several factors 
like lymphotoxin (LT). It should be noted that although 
LT-α, LT-β, and LT-β receptor deficient mice have a lack 
of lymph nodes and Peyer’s patches, and do not produce 
intestinal IgA [100, 101], but whether IgA production in 
the reticuloendothelial organs like bone marrow would 
also be affected remains to be investigated. 
Despite isolated defects in several cytokines including 
IL-4, IL-6, IL-7, and IL-10, which have been found in 
SIgAD patients [13], it should be noted that synergistic 
action between cytokines occurs in the secondary lym-
phoid organs and leads to robust IgA production. There-
fore, combined abnormal cytokine releasing pattern at lo-
cal sites of B-cell proliferation or cytokine kinetics can 
also account for the failure of IgA production in SIgAD 
patients. Alternatively, some cytokines may act as inhibi-
tory factors of B lymphocyte function. Further studies, 
which take these variables into account, will need to be 
undertaken.
Apoptosis
Increased apoptosis of B cells during an immune re-
sponse can be involved in the reduction of IgA secretion 
and differentiation into plasma cells or long-term IgA 
switched memory B cells and plasma cells. Initial investiga-
tions studied the cellular and molecular mechanisms un-
derlying IgA deficiency, and reported that IgA-positive B-
lymphocytes can be found in patients with IgA deficiency 
[102]. Decreased number of CD138+XBP1+ plasma cells 
was observed upon stimulation with TGF-β and IL-10, but 
when the same stimulation was used in combination with 
IL-4, B cells were able to induce transcription of intracel-
lular XBP-1, indicating that the defect is not due to the in-
ability of B cells to differentiate into plasma cells. These 
results seem to be consistent with reports showing in-
creased apoptosis of CD20+IgA+ B cells as a part of casual 
etiology of SIgAD [43, 103]. In this regard, Hammarström 
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and colleagues [45] reported that SIgAD patients lack sur-
face IgA B cells, and the combination of IL-4, IL-21, and 
the anti-CD40 monoclonal antibody can prevent apoptosis 
of these cells in SIgAD patients, and result in reconstitution 
of IgA secretion. A notable point is that in spite of the intact 
genes and molecular mechanisms of IgA recombination, 
and in addition to the reports that show low surface IgA-
positive B cells in patients with SIgAD, the existence of a 
defect in the long-term survival of IgA secreting cells and 
memory B cells should be considered [14].
Microbiota Defect
Production of IgA in the intestinal mucosa depends on 
colonization with environmental microbes; however, 
Bendalec and colleagues [104] showed that the interac-
tion of the microbiome for IgA stimulation is not specific 
to particular bacterial epitopes, and produced IgA that 
can widely react with different components of the gut 
commensal microbes. 
Hence, it can be hypothesized that defects in commen-
sal intestinal microbes cause IgA deficiency. Interestingly, 
it has been manifested that despite strongly reduced IgA 
level observed in intestinal mucosa of germ-free mice, 
there was no IgA deficiency, and the serum IgA level was 
about half the normal quantity [105–107]. This suggests 
that because of separate circuits of mucosal and systemic 
IgA production, amount of serum IgA can be produced 
independently in mucosal layers. Although the gastroin-
testinal tract is the biggest mucosal surface area of the hu-
man body, other mucosal surfaces have a significant role 
in the final IgA production [108]. In general, however, 
commensal intestinal microbes are crucial for adjusting 
the level of induction of IgA synthesis. These SIgAD pa-
tients are expected to show more serious gastrointestinal 
problems if defects are present in microbiota. In addition 
to the necessity to study this concern, extensive research 
is needed to determine whether IgA production leads to 
defects in the bone marrow and spleen of SIgAD patients.
Animal Models for SIgAD
Animal models of human disease are commonly uti-
lized to gain insight into the pathogenesis of diseases or 
to investigate the efficacy of potential therapeutic regi-
mens and drugs. There are a number of reports on wolves, 
chickens and several breeds of dogs with IgA deficiency 
but the molecular basis of these deficiencies has not been 
discovered [109–112]. Since in mice, almost any given 
gene can be a manipulated, several suspected genes re-
lated to the IgA production have been switched off and 
examined for immunological and clinical consequences. 
Harriman et al. [113], for the first time, targeted the 
switch and constant regions of the IGHA gene in mice 
and produced IgA-deficient homozygous mice (IgA–/–).
Subsequently, a member of the TNF superfamily were 
targeted and BAFF, APRILL, and TACI KO mice models 
have been generated [78, 80, 98]. Another notable model 
was wasted mouse, presenting a phenotype characteristic 
of ataxia telangiectasia, and Kaiserlian et al. [114] pro-
posed these mice with concurrence of IgA deficiency. The 
most important issue is that even though these animal 
models are phenocopies of IgA deficiency in humans, 
none of them naturally happens and there is no animal 
model available yet which simulates the human IgA defi-
ciency. Therefore, for better understanding of the patho-
genesis of IgA deficiency and due to heterogeneous eti-
ologies different animal models might be developed.
Conclusion
The purpose of the current review was to investigate 
the pathogenesis of SIgAD. We still need to increase our 
knowledge about the mechanisms and sites of alternative 
IgA CSR, as SIgAD can be associated with different PIDs. 
Despite these promising results, 1 question remains re-
garding the compensatory and complementary mecha-
nisms for IgA CSR and production: why these patients 
generally do not have solely IgA. The mechanisms leading 
to SIgAD are most likely multifactorial rather than mono-
genetic and it can be speculated that several pathways 
controlling B cell functions or regulatory regions of the 
IGHA gene may be identified as underlying etiologies in 
different SIgAD patients. Thus, results of available animal 
models cannot be applied on humans with SIgAD, and 
for better understanding of the pathogenesis of IgA defi-
ciency, different animal models need to be designed.
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